Recovering scientist turned early stage VC A biotech optimist fighting gravity

Caveat Subscriptor When Academia Touts A Breakthrough
March 31, 2017

This blog was written by Nessan Bermingham, CEO of Intellia Therapeutics, as part of the From The Trenches feature of LifeSciVC   Academic discoveries are oxygen for entrepreneurs. But, caveat subscriptor – be careful what you sign. Even high profile

1 Comment

The Inescapable Gravity Of Biotech’s Key Clusters: The Great Consolidation Of Talent, Capital, & Returns
March 21, 2017

Two key geographic clusters dominate the biotech landscape today. These two areas, Boston and San Francisco, combine a unique blend of biomedical science, venture capital, entrepreneurial talent, risk-taking culture, and geographic density. Other regions have some or all of these


The Hunt For Novel Treatments Against Deadly Bacteria:  Spero Therapeutics And Its Potentiators
March 16, 2017

This guest blog was written by Troy Lister, Head of Chemistry, and Cristina Larkin, Chief Commercial Officer, of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. A national security threat equivalent to terrorism?  This is how

1 Comment

Of Abundance And Scarcity In Venture Capital
March 13, 2017

As a biotech investor, it’s been fascinating to watch the Snapchat IPO and the fanfare around this $25B sensation following its offering as a “camera” company. As one of the big tech unicorns, it’s justifiably gotten considerable attention in the

1 Comment

VC-Backed Biotech Ecosystem: A Market In Healthy Equilibrium
March 10, 2017

Despite the volatility of biotech stocks in the public markets, the VC-backed private biotech ecosystem has been in remarkable equilibrium for much of the last decade. e·qui·lib·ri·um. noun.  a state in which opposing forces or influences are balanced. As I’ve noted


From Poisons To Pills: Peptides
February 10, 2017

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. When a taxi driver finds out the name of my company, I am inevitably asked, “What does Bicycle Therapeutics


Helping Others Conquer The Mountain
February 8, 2017

Snow sports are a passion of mine; almost any day up on a mountain is a great day. By combining this passion with a bigger purpose, I’ve recently tapped into a true vein of inspiration, integrating both my professional and

Leave a comment

Seven Important Policy Agenda Items For BioPharma
January 31, 2017

President Trump’s tenure as the 45th POTUS has begun with even more fireworks than most pundits predicted – protests, marches, bans, and lots of other drama. The coastal Twitter/Facebook bubbles are exploding with anger and rage, while the Trump populists

1 Comment

Talent In The Biotech Gig Economy
January 31, 2017

This blog was written by Jeb Keiper, CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Walking the streets of Union Square in mid-January torrential rain, we had the good fortune of sharing the


Delinia Delivers An Exciting Autoimmune Therapy To Celgene
January 26, 2017

Today Celgene announced its acquisition of Delinia for $300 million upfront, and up to $475 million in milestones, adding to its growing portfolio of novel immunology medicines. Delinia’s rapid trajectory over the past fifteen months has been exciting to watch: this

Leave a comment

Alzheimer’s Research: Diversity Now
January 19, 2017

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC.   In my February 2016 post, I wrote “if some of the current generation of high-profile,

1 Comment

After the San Francisco Rain: Looking On The Bright Side In 2017
January 18, 2017

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. The biotech industry was reeling after the 2016 J.P. Morgan Healthcare Conference, with many commentators foretelling doom in the

1 Comment